Physician profile
Matthew Sutherland
NPI 1891310991
$2,544.91
in general payments reported to CMS, 2019-2025
18 companies · $637 in 2025
The $637 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $47.16 · 2021: $248 · 2022: $684 · 2023: $485 · 2024: $443 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,481 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,481.44 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $450.59 | 2022-2025 | Stelara, Tremfya |
| Regeneron Pharmaceuticals, INC. | $319.29 | 2024-2025 | Dupixent |
| Janssen Pharmaceuticals, INC | $313.29 | 2020-2022 | |
| Abbvie INC. | $296.16 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.55 | 2021-2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $152.55 | 2023-2025 | Entyvio, Ninlaro |
| Bayer Healthcare Pharmaceuticals INC. | $140.80 | 2022-2023 | |
| Janssen Biotech, INC. | $122.83 | 2025 | Tremfya |
| Ardelyx, INC. | $103.94 | 2025 | Ibsrela |
| Glaxosmithkline, LLC. | $99.99 | 2022 | |
| Qol Medical, LLC | $91.58 | 2025 | Sucraid |
| Gilead Sciences, INC. | $75.97 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $68.08 | 2021-2025 | Lifevest |
| Capsovision, INC. | $49.47 | 2024 | Capsocam Plus |
| Boston Scientific Corporation | $37.06 | 2023-2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $25.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.67 | 2022 | |
| Erbe USA INC | $20.09 | 2025 | Vio3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Sutherland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.